Rationale and protocol of the Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

Nephrology Dialysis Transplantation

Volumn 35, Issue 2, 2020, Pages 274-282

  Heerspink, Hiddo J L ^a,b   Stefansson, Bergur V ^c   Chertow, Glenn M ^d,ap   Correa Rotter, Ricardo ^e,ac,ap   Greene, Tom ^f,ap   Hou, Fan Fan ^g,ap   Lindberg, Magnus ^c   McMurray, J ^ap   Rossing, Peter ^i,j   Toto, Roberto ^k   Langkilde, Anna Maria ^c   Wheeler, D C ^ap   Heerspink, H J L ^ap   Rossing, P ^ap   Toto, R ^ap   Stefansson, B ^ap   Langkilde, A M ^ap   Pfeffer, Marc A ^m   Pocock, Stuart ⁿ   Swedberg, Karl ^o   Rouleau, Jean L ^p   Chaturvedi, Nishi ^l   Ivanovich, Peter ^q   Levey, Andrew S ^r   Christ Schmidt, Heidi ^s   Mann, Johannes ^t   Held, Claes ^u   Varenhorst, Christoph ^u   Holmgren, Pernilla ^u   Hallberg, Theresa ^u   Douthat, Walter ^v   Filho, Roberto Pecoits ^w   Cherney, David ^x   Persson, Frederik ⁱ   Haller, Hermann ^y   Wittmann, István ^z   Khullar, Dinesh ^aa   Naoki, Kashihara ^ab   Escudero, Elizabeth ^ad   Isidto, Rey ^ae   Nowicki, Michal ^af   Batiushin, Mikhail ^ag   Kang, Shin Wook ^ah   Teruel, José Luis Górriz ^ai   Furuland, Hans ^aj   Bilchenko, Oleksandr ^ak   Mark, Patrick ^al   Dwyer, Jamie ^am   Umanath, Kausik ^an   van Bui, Pham ^ao   more..

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^c ASTRAZENECA R AND D   (Sweden)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Salvador Zubirán   (Mexico)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g SOUTHERN MEDICAL UNIVERSITY   (China)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ STENO DIABETES CENTER   (Denmark)

^j UNIVERSITY OF COPENHAGEN   (Denmark)

^k UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁿ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^o UNIVERSITY OF GOTHENBURG   (Sweden)

^p MONTREAL HEART INSTITUTE   (Canada)

^q NORTHWESTERN UNIVERSITY   (United States)

^r TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^s University of Iowa   (United States)

^t UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^u UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^v Hospital Privado   (Argentina)

^w PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^x UNIVERSITY HEALTH NETWORK   (Canada)

^y HANNOVER MEDICAL SCHOOL   (Germany)

^z UNIVERSITY OF PÉCS   (Hungary)

^aa New Delhi Saket   (India)

^ab KAWASAKI MEDICAL SCHOOL   (Japan)

^ac INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^ad HOSPITAL NACIONAL ARZOBISPO LOAYZA   (Peru)

^ae HealthLink   (Philippines)

^af MEDICAL UNIVERSITY OF LODZ   (Poland)

^ag ROSTOV STATE MEDICAL UNIVERSITY   (Russian Federation)

^ah Yonsei University   (South Korea)

^ai HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^aj Medicin Centrum   (Sweden)

^ak Kharkiv City Clinic of Urgent and Emergency Care   (Ukraine)

^al QUEEN ELIZABETH UNIVERSITY HOSPITAL   (United Kingdom)

^am VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^an HENRY FORD HOSPITAL   (United States)

^ao Nguyen Tri Phuong Hospital   (Viet Nam)

^ap Henry Ford Hospital ^*

more..

Author keywords

Chronic kidney disease; Dapagliflozin; Randomized controlled clinical trial; Sodiumglucose co transporter inhibitor

Indexed keywords

ALBUMIN; CREATININE; DAPAGLIFLOZIN; PLACEBO; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ADULT; ADVERSE OUTCOME; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL PROTOCOL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HEART DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RISK REDUCTION; URINARY EXCRETION; AMINO ACID URINE LEVEL; CARDIOVASCULAR MORTALITY; DRUG TOLERABILITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; RISK FACTOR; ADOLESCENT; AGED; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPLICATION; DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION RATE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSIDES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RESEARCH DESIGN; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; YOUNG ADULT;

EID: 85079082162     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfz290     Document Type: Article

References (14)

1. Heerspink HJ, Perkins BA, Fitchett D et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes: cardiovascular and kidney effects, potential mechanisms and clinical applications. Circulation 2016; 134: 752-772
2. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128
3. Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-657
4. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347-357
5. Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380: 2295-2306
6. Dekkers CCJ, Gansevoort RT, Heerspink HJL. New diabetes therapies and diabetic kidney disease progression: the role of SGLT-2 inhibitors. Curr Diab Rep 2018; 18: 27
7. Rajasekeran H, Cherney DZ, Lovshin JA. Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease? Curr Opin Nephrol Hypertens 2017; 26: 358-367
8. Komoroski B, Vachharajani N, Boulton D et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009; 85: 520-526
9. Lundkvist P, Sjostrom CD, Amini S et al. Dapagliflozin once-daily and exenatide once-weekly dual therapy: a 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes. Diabetes Obes Metab 2017; 19: 49-60
10. Al Jobori H, Daniele G, Adams J et al. Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. Diabetes Obes Metab 2017; 19: 809-813
11. Dekkers CCJ, Wheeler DC, Sjostrom CD et al. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and stages 3b-4 chronic kidney disease. Nephrol Dial Transplant 2018; 33: 2005-2011
12. Pleros C, Stamataki E, Papadaki A et al. Dapagliflozin as a cause of acute tubular necrosis with heavy consequences: a case report. CEN Case Rep 2018; 7: 17-20
13. McMurray J. Dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF). Presented at the European Society for Cardiology Congress 2019, 1 September 2019, Paris, France
14. Perkovic V, de Zeeuw D, Mahaffey KW et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS program randomised clinical trials. Lancet Diabetes Endocrinol 2018; 6: 691-704